A First Step Towards Overcoming the Limitations of Highly Active Antiretroviral Therapy

This clinical study, led by the National Institute of Allergy and Infectious Diseases (NIAID), aims to verify whether early administration of highly active antiretroviral therapy (HAART) in the early stages of HIV infection can prevent permanent loss of immune cell function. The current HIV treatment market is dominated by INSTI-based triple combination drugs, such as Biktarvy from Gilead, which have become the standard of care (SOC) by maximizing viral suppression. However, these treatments still have limitations in fully restoring the already damaged immune system. This study is attracting attention from both academia and industry as it seeks to identify the optimal timing for treatment that can induce immune reconstitution beyond simple viral replication inhibition.

Precision Immune Monitoring Using Leukapheresis

The researchers plan to perform leukapheresis, a procedure that selectively separates a large amount of leukocytes from the patient's blood, to obtain cell samples for detailed analysis. This technique allows for the acquisition of a large number of key immune cells, such as B cells, CD4+ T cells, and natural killer (NK) cells, compared to conventional blood collection, which is essential for monitoring long-term changes in immune cell function at the cellular level. In particular, by tracking immunological parameter changes before and after the introduction of HAART, starting from treatment-naive patients, the study aims to clarify the causal relationship between immune suppression-inducing factors and viral suppression mechanisms.

Insights Through Comparative Study of Early and Chronic Infection Patients

This clinical trial is designed as a comparative cohort, comparing a group of patients with primary HIV infection and a group of patients with chronic HIV infection in equal numbers. This design will allow for statistical verification of the impact of disease progression on immune cell regeneration and maintenance, and ultimately demonstrate the clinical superiority of early intervention. By quantifying the differences in cellular exhaustion and the rate of residual viral reservoir formation according to the duration of infection, the study is expected to provide valuable basic data for the development of next-generation HIV therapeutic vaccines and cure pipelines in the biopharmaceutical industry.

Long-Term Impact on the Development of Curative Agents

The global HIV therapeutics market is estimated to be worth approximately USD 34.0 billion to USD 39.0 billion by 2025, and there is a high unmet medical need for curative agents. The longitudinal immune cell database to be derived under the leadership of the National Institute of Allergy and Infectious Diseases (NIAID) can serve as a scientific milestone for the development of next-generation immunotherapies and gene therapies beyond Biktarvy. If the functional recovery mechanism of a specific cell population is proven, it will provide global pharmaceutical companies with new target molecules and drug development platforms, leading to a paradigm shift in HIV treatment from lifelong medication to cure.